To evaluate the contribution of the glycosphingolipid pathway to the TNF-induced melanoma cell dedifferentiation process, we monitored the impact of eliglustat, an inhibitor of glucosylceramide synthase (GCS), by RT-qPCR on various markers of melanoma dedifferentiation. The gene discussed is UGCG; the disease is melanoma.